VIENNA—With actionable genomic alterations already being targeted by some existing approved drugs in patients with breast cancer genomic analysis was being hailed at the St Gallen Breast Cancer Conference as a way to expand the range of individualized cancer drugs by revealing more pathways responsible for breast cancer response and outcome. Farbice André MD, PhD, from the Institut Gustave Roussy in Villejuif, France, discussed the scope for bridging the gap between new genomic technologies and their application in the real world with Oncology Times reporter Sarah Maxwell.
You may also like...
Adjuvant Chemotherapy Extends Life in Locally Advanced Bladder Cancer 13 Mar, 2015 PD-L1 Immunotherapy Delayed Triple Negative Breast Cancer Progression 31 Oct, 2018 Active Surveillance Better for Which Renal Cell Cancers? 17 Apr, 2017 Tumor Microenvironment: Tumor Infiltrating Lymphocyte Score Predicts Breast Cancer Outcome 27 Mar, 2015
- Previous story Endocrine Therapy in Premenopausal Breast Cancer: Most Effective Not Always Best
- Next story International Research and Consensus Needed to Interpret Breast Cancer Genomics Data
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014